Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, prospective, randomized, open-label, controlled phase II study to test
the addition of the CDK4/6 inhibitor ribociclib to anti-hormonal treatment as maintenance
therapy in patients with disease control (at least stable disease) after 1st line
chemotherapy.